E-cadherin-160 C/A promoter polymorphism and risk of pancreatic carcinoma in Chinese population

Cancer Genetics and Cytogenetics
Yang FeiJieming Gong

Abstract

Recent studies have implicated E-cadherin-160C/A single-nucleotide polymorphism (SNP) in susceptibility to and early onset of some cancers. We investigated the role of E-cadherin-160 C/A SNP in Chinese pancreatic carcinoma patients without dominant family history by genotyping 254 patients and 101 controls. The risk of cancer for CC genotype individuals was less than half that of AA individuals [odds ratio (OR) = 0.41; 95%confidence interval (95%CI) = 0.18-0.96]. Furthermore, patients with the CC and CA genotypes whose tumors were stages III (T(4)N(x)M(0)) and IV (T(x)N(x)M(1)) (OR = 0.38; 95%CI = 0.17-0.83), poorly differentiated (OR = 0.28; 95%CI = 0.09-0.84), and left-sided (OR = 0.45; 95%CI 0.21-0.98) were associated with significantly lower risk than AA patients. Young (60 years old or younger) AA patients had a 5-year lower mean age at onset than CC/CA patients (P = 0.02). Young male AA patients had worse disease-specific survival than CC/CA patients (P = 0.002). Thus, contrary to Canadians and Portuguese, the AA (rather than CC) genotype is associated with increased susceptibility and advanced pancreatic carcinoma in Chinese patients, suggesting a more complex relationship between the SNP and pancreatic carcinoma risk, p...Continue Reading

References

Feb 11, 1988·Nucleic Acids Research·S A MillerH F Polesky
Aug 1, 1995·Proceedings of the National Academy of Sciences of the United States of America·K YoshiuraS Hirohashi
Nov 20, 1997·Journal of Cellular Physiology·M MareelM Bracke
Apr 16, 1998·Nature·P GuilfordA E Reeve
Sep 23, 1998·Human Mutation·G BerxF van Roy
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·J A EfstathiouW F Bodmer
Jul 9, 1999·The Journal of Pathology·E BraungartM J Atkinson
Apr 6, 2001·International Journal of Cancer. Journal International Du Cancer·S DroufakouI R Hart
Jul 31, 2001·Surgical Oncology·W G Jiang, R E Mansel
Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Paul D P PharoahDavid Huntsman
Feb 13, 2004·International Journal of Cancer. Journal International Du Cancer·Tine Hajdinjak, Natasa Toplak
Mar 3, 2005·Japanese Journal of Clinical Oncology·Toshiyuki KamotoOsamu Ogawa
Jun 22, 2005·Pancreas·Xiaozhong Guo, Zhongmin Cui
Apr 25, 2006·Nature Reviews. Cancer·Keiichi I Nakayama, Keiko Nakayama
Feb 19, 2008·Biochimica Et Biophysica Acta·Sujeong YangRaymond Bujdoso
May 13, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Guiying WangZ W Luo

❮ Previous
Next ❯

Citations

Feb 15, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Shun-Fa YangPo-Hui Wang
Oct 3, 2014·Molecular Biology International·Gongcheng LiLong-Cheng Li
Nov 6, 2012·Fertility and Sterility·Hsiu-Ting TsaiPo-Hui Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.